Should patients with benign prostatic hypertrophy stop taking doxazosin in the light of the ALLHAT study?
Cheng
Tsung O
TO
D000317:Adrenergic alpha-Antagonists / Q000008:administration & dosage / Q000009:adverse effects*; D000924:Anticholesteremic Agents / Q000009:adverse effects; D000959:Antihypertensive Agents / Q000009:adverse effects; D002986:Clinical Trials as Topic; D017292:Doxazosin / Q000008:administration & dosage / Q000009:adverse effects*; D004359:Drug Therapy, Combination; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D018120:Finasteride / Q000627:therapeutic use; D018149:Glucose Intolerance / Q000188:drug therapy; D006801:Humans; D006949:Hyperlipidemias / Q000188:drug therapy; D006973:Hypertension / Q000188:drug therapy*; D008297:Male; D009203:Myocardial Infarction / Q000139:chemically induced / Q000517:prevention & control*; D011470:Prostatic Hyperplasia / Q000150:complications* / Q000188:drug therapy
D000317:Adrenergic alpha-Antagonists; D000924:Anticholesteremic Agents; D000959:Antihypertensive Agents; D004791:Enzyme Inhibitors; D018120:Finasteride; D017292:Doxazosin